Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa

NCT06926192 · tracked via the Priya Life Science China tracker

Sponsor

Peking Union Medical College

Phase

Observational

Started

2020-01-01

Last updated

2025-04-16

Condition(s) studied

Hidradenitis Suppurativa (HS)Hidradenitis Suppurativa (Acne Inversa)Secukinumab

Investigational drug(s) / intervention(s)

Surgery combined with secukinumab

Surgery combined with secukinumab: Surgery combined with secukinumab

Study summary

This study aims to retrospectively analyze the efficacy and safety of secukinumab combined with surgery in treating moderate to severe HS in real-world clinical practice, providing clinical practioners with real-world evidence in HS treatment.

Eligibility

Sex

ALL

Min age

—

Max age

80 Years

Healthy volunteers

Inclusion Criteria: 1. Patients aged 18 to 80 years old with moderate-severe (Hurley II-III) HS 2. The diagnosis of HS was confirmed by histopathological examination in the Department of Pathology of our hospital 3. Patients with HS who received secukinumab combined with surgery in the Department of Dermatologic Surgery of our hospital 4. Patients with complete clinical data followed up for at least 1 year Exclusion Criteria: 1. Patients lost to follow-up 2. Patients with less than one year of follow-up 3. Patients who received additional adjuvant therapy during the follow-up period

Primary outcome measure(s)

HiSCR — week 52
at least a 50% reduction in total AN count, with no increase in abscess count, and no increase in draining fistula count relative to baseline)

Trial sites (1)

Facility	City	Region	Status
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College	Nanjing	Jiangsu	Recruiting

More Peking Union Medical College trials in China

Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS Starting soon

Nutritional Support on Outcomes and Cost-effectiveness for Patients at Risk Starting soon

Effect of Hypophosphatemia on Neuro-excursion Efficiency During Mechanical Ventilator Weaning Recruiting

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing Recruiting

Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway Starting soon

Other trials for the same condition

A Prospective Study to Assess the Efficacy of IL-17 Inhibitors on Subclinical Enthesitis in Patients With Moderate to Severe Psoriasis Based on Power Doppler (PD) Ultrasonography (PDUS) Recruiting

A Single-center, Prospective, Self-controlled, Observational Real-world Study of the Efficacy and Safety of Anti-IL-17A/F Monoclonal Antibody Combined With Non-ablative Dot Laser for the Treatment of Mild to Moderate Hidradenitis Suppurativa Starting soon

A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients Recruiting

A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa Recruiting

Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06926192 on ClinicalTrials.gov ↗ ← All trials in China